A new treatment option for patients with advanced non-small-cell lung cancer (NSCLC) harboring a KRASG12C mutation is on the horizon.Read More
Researchers presented preliminary results of a phase 2 clinical trial in which they gave patients with resectable pancreatic cancer neoadjuvant multiagent chemotherapy.
Erlotinib prolongs survival of late-stage non-small cell lung cancer patients with the EGFR mutation. Researchers recently tested whether the drug would improve cure rates when given to early-stage patients.
Women with wound complications after mastectomy and immediate breast reconstruction do not have a higher risk of breast cancer recurrence, despite potential delays in adjuvant therapy, says new study.
Cleveland Clinic research uncovers the influence of cancer-associated fibroblasts and secretion of the cytokine IL-17A on stem cell renewal, chemotherapy resistance and tumor spread in colorectal cancer.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Recurrence scores based on a 16-gene assay accurately predict clinical outcomes in patients with surgically treated clear cell renal cell carcinoma, Cleveland Clinic researchers report.
Cleveland Clinic’s multidisciplinary approach to cancer care is demonstrated in the new Tumor Board webcast video series. The series launches with an HER2-positive breast cancer case.
Treatment gaps in renal cell cancer can compromise care. Knowing where they are is the first step toward addressing them; the next is to widen the use of evidence-based medicine.
In the Y90 radioembolization procedure, interventional radiologists deliver radioactive (Y90) resin or glass-based particles to liver tumors by catheter and provide a continuing radiation dose.